Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.1,2
- Cologuard Plus — An At-Home Stool DNA Test for Colorectal Cancer Screening
- Landiolol (Rapiblyk) for Short-Term Rate Control in Supraventricular Tachycardia
- Concizumab (Alhemo) for Hemophilia A and B with Inhibitors
- Mirikizumab (Omvoh) – An IL-23 Antagonist for Crohn's Disease
- In Brief: A Home Test for Chlamydia, Gonorrhea, and Trichomoniasis
RELEASE
Fitusiran (Qfitlia – Sanofi), a subcutaneously injected, antithrombin-directed, small interfering ribonucleic acid (siRNA), has been approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥12 years old who have hemophilia A with or without factor VIII inhibitors or hemophilia B with or without factor IX inhibitors. It is the first antithrombin-lowering therapy to become available in the US for treatment of hemophilia.
STANDARD TREATMENT ― Hemophilia A is an X-linked bleeding disorder (estimated prevalence 1:5000 live male births) characterized by insufficient levels of coagulation factor VIII. Prophylaxis with intravenous factor VIII replacement therapy is the standard of care, but >30% of patients with severe hemophilia A develop neutralizing antibodies (inhibitors) to factor VIII and require alternative treatments.
…